KoreaFilings

Daborink (다보링크)

KOSDAQ · KRX: 340360

I don't have reliable information about a specific Korean company called "Daborink (다보링크)" in my training data. Rather than provide potentially inaccurate details about its sector, market listing, or operations, I cannot write the paragraph you've requested. I recommend verifying the company name and consulting official sources such as the Korea Exchange (KRX) website or the company's official materials for accurate information.

Filing timeline

criticalspotted 14:15 KST
Daborink (KRX: 340360)

Terra Science (테라사이언스) discloses 34.39% stake in Daborink (다보링크) following share transfer agreement amendment

  • Terra Science reported a total holding of 14,922,379 shares in Daborink (KRX: 340360, KOSDAQ), representing 34.39% of shares outstanding, as of the filing dated 24 September 2024.
  • Of the total holding, 11,279,950 shares (26.00%) are classified as shares subject to a voting agreement or contractual arrangement (계약주식).
  • The filing was triggered by two events: an amendment to an existing share transfer agreement (주식양수도계약 변경합의서 체결) and the execution of a new share transfer agreement (주식양수도 계약서 체결); the reported change in shareholding and percentage was zero (0 shares, 0.00 percentage points).
View original DART filing ↗
criticalspotted 16:48 KST
Daborink (KRX: 340360)

Terra Science (테라사이언스) discloses 34.39% stake in Daborink (다보링크), KOSDAQ 340360

  • Terra Science reported total holdings of 14,922,379 shares (34.39%) in Daborink as of the filing dated 2 September 2024.
  • Shares with voting rights subject to contractual control (의결권 있는 주식) stand at 10,679,950 shares, representing 24.62% of total shares.
  • The report was triggered by four concurrent events: amendment to a share transfer agreement, execution of a share-collateral loan agreement, execution of a new share transfer agreement, and execution of a share transfer succession consent.
View original DART filing ↗

AI-generated summaries of public DART filings. May contain errors — always verify against the original (linked). Not investment advice.